Silence’s siRNA candidate for cardiovascular disease continues to deliver in Phase 2 trial

Si­lence Ther­a­peu­tics has un­veiled ad­di­tion­al da­ta from a mid-stage tri­al of its siR­NA ther­a­py can­di­date in cer­tain peo­ple at risk of heart episodes, set­ting the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.